Connect with us

Stocks

Most Interesting Assets on the U.S. Stock Market

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

This review comprises the stocks with the highest yield over the last 30 days.

 

STAAR Surgical Company (STAA)

STAAR Surgical Company was founded back in 1982. With its subsidiary companies, it develops, produces, and sells implantable ophtalmic lenses and systems for their implementation. Implantable lenses is a radical approach to treating such common vision disorders as myopia, long sight, astigmatism, and presbyopia. The company sells its products directly through its representatives in the UK, Germany, Spain, Canada, Singapore, the US, and Japan, and in 75 countries more through its independent resellers.

Among STAAR’s subsidiaries, one can name Domilens Vertrieb fuer medizinische Produkte GmbH, STAAR Japan Inc, and STAAR Surgical AG. The company falls into Healthcare (Medical Instruments & Supplies) sector.

Over the last month, STAAR shares have grown by 70.36%. Such a growth was caused by the Q1 earnings report that showed so good result that the profit forecast drastically increased for the whole 2018, namely, from 2% all the way to 20%! This is also because of the good results in the Asian market.

In Q1 2018, STAAR net profit amounted to 0.6M USD, or $0.01 per share, against -$2.2M or $0.05 per share in Q1 last year. The biggest profit share was brought by Visian ICL, the product the company expects even more from moving forward. This product is very much like a regular contact lens implemented into an eye. This allows people with myopia or far sight to stop using contact lenses, which solves the so-called ‘dry eye’ issue. Implantable lens implementation is done by a physician, but costs far less than a regular eyesight recovery operation.

In 2018, STAAR is going to continue investing into Visian ICL clinical trials, which means more profit and good earnings reports in the future.

Technically, there is an ascending trend forming, with the price being above the 200-day SMA. The key resistance at $17 had been active since December but finally got broken out, while the immediate support is now at $22. There are no fresh resistance levels on the chart yet, as the price is at its highs since the stock’s inception. Short float is very low, at 2.36%, while the investment funds own over 79.9% of the shares and have not sold them recently.

 

PolarityTE, Inс. (COOL)

PolarityTE, Inс. is a biotech company founded back in 1998, developing regenerative tissue and biomaterials for medical purposes. PolarityTE results in regeneration are really unique.

PolarityTE technology is based on the patient’s healthy tissue which then creates a self-spreading product designed to strengthen and stimulating patient’s cells for regeneration purposes. Instead of making synthetic or third-party materials, PolarityTE uses patient’s tissue, which helps develop the regeneration process much better. The innovative PolarityTE method enables speeding up the recovery process.

Among the company subsidiaries, one can name Jesse M. Sutton Foundation, Majesco Entertainment, Zift Interactive LLC, and Paradigm Shift Universal, Inc. The company falls into Healthcare/Biotechnology sector.

Over the last month, PolarityTE share price went up by 51.93%, mainly because of its major product called SkinTE. Those who already tried it are very happy about it, which is an additional marketing stimulus for the company.

Here’s some feedback of one of the patients: ‘I damaged my skin badly in a motorbike accident a few years ago. The wounds were so serious that no medical care could help, as the skin just would not recover. Finally, they had to transplant the skin, but this lasted for a few months, while the wounds were bleeping, and when they took off the bandage, around 50% of the transplanted skin was left there. After that, I decided to use SkinTE, and just in a few weeks the skin fully recovered, including even the hair coat.’

More and more reviews like this one are coming in everyday. SkinTE helps recover skin after fire burns, chemical burns, lacerations, and other skin damages. The recovery process is much more speedy than regular one, and is very convenient. The company is using this good situation to find resellers in the East Coast in order to boost sales.

Until April, the stock was downtrending, but SkinTE news was a real game changer for PolarityTE, Inc, as it broke out the 200-day SMA, signaling for a newborn ascending trend.

Meanwhile, the investment funds’ PolarityTE buys grew by 14.23%, while the board members still have around 45% of shares and have not sold them recently.

Short float at 18.78% is an additional stimulus for the stock growth, as the bears have to close their positions, thus pushing the price higher.

The closest support that may be reached by a pullback is at $22, while the closest support is at around $30.

 

IntriCon Corporation (IIN)

IntriCon Corporation (IIN) was founded back in 1930, and is currently developing, producing and selling software for medical appliances, hearing kits, and audio communication devices. IntriCon also offers earsets for law enforcement institutions, aviation, and military, as well as small versions for musicians and security guards. IntriCon Corporation was formerly known as Selas Corporation of America.

Among the company subsidiaries, one can name EarVenture LLC, Hearing Help Express, Inc., IntriCon Datrix Corporation, IntriCon GmbH, IntriCon PTE LTD, IntriCon Tibbetts Corp, PC Werth Ltd, Resistance Technology, Inc., RTI Electronics, Inc., and RTI Technologies PTE LTD. The company stock falls into Industrial Goods (Industrial Electrical Equipment) category.

Over the Last month, IntriCon increased the investor profit by 50.76%, mostly because of the Q1 earnings report that exceeded expectations. The company’s net profit reached $25.4M, which is 19.6% bigger than last year (around $21.2M). The shareholders’ net profit in Q1 2018 was $769,000, or $0.10 per share, compared to -$270,000 or -$0.04 per share in Q1 2017.

This year, the company focuses on the hearing aid and continuous sugar monitoring devices. Both products are going to be very much in demand, as the ‘baby boomers’ are getting old but are still used to the gadgets that make their lives more comfortable.

Diabetes is one of the most serious problems in the US, as more and more elderly Americans get this diagnosis. In case such patients do not stick to the diet and workout plans, their health becomes worth further. Such people have to always control their sugar level, while the devices used for that purpose used to be large and difficult to use. IntriCon and Medtronic PLC (MDT) succeeded in making them more compact and easy to use, allowing the patients to monitor their sugar level without any major issues.

Medtronic PLC controls over 81% of the sugar level measuring device market, so IncriCon partnering with them allows the company to boost their sales even further. As of now, InctriCon is going to rent additional 37 000 square feet of facilities to boost the production.

The investor sentiment can be easily confirmed by tech analysis figures. The price is above the 200-day SMA, which means there’s an uptrend in place. There are no resistance levels near the price, as the company is making its record highs.

The investors are a bit worried about the large volumes as the price is going up, so a large correction may occur this week, with the price reaching $19 or even $17.

Meanwhile, the short float is just 2.44%, and the investment fund share is 2.27%.

Disclaimer

Any forecasts contained herein are based on the authors’ particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.

Featured image courtesy of Shutterstock. 

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 15 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Analysis

Boeing Still a Good Investment, but Not Now

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

In one of our previous articles, we spoke about the rising demand of pilots and air transportation, which made us focus on relevant companies. Another important aspect here is aircraft, without which no air transportation is possible. So today, we’ll analyze one of the largest aircraft manufacturers out there, Boeing.

Boeing Company (NYSE: BA) is a leading aircraft, military and space equipment manufacturer. Headquartered in Chicago, IL, the company mostly operates in Seattle, WA. Boeing is among the top three military equipment companies in the US by the yearly order volume. Around 50% of the company’s budget accounts for military orders.

Over the last four years, Boeing’s yearly revenue is always somewhere near $90B, while the net profit is steadily growing.

Since 2014, the company’s equity was going down, with the debt growing at the same time, and thus the debt-equity ratio is currently not the best one.

Despite the debt, however, the investors get the dividends regularly, and those have been growing speedily since 2014: from $1.94 per share that year to $6.50 in 2018. Meanwhile, the growing demand led to Boeing supplying 763 aircraft in 2017. This was a record high, and the earnings went up from $4.985B to $8.197. The price per share also rose by over 100%, breaking out $300. In 2018, the company is going to supply 912 aircraft, or 20% more.

Boeing Contracts

Recently, Boeing got a contract for $62.7M which included maintenance and modification of F/A-18 и EA-18G. The contract is expected to be fulfilled by Sep 2019.

Another contract won by Boeing is worth $805M and includes developing, manufacturing, testing, and supplying for pilotless aircraft to the US Air Force by 2024.

The US Air Force also has yet another contract with Boeing, which is worth $9.20B and includes both aircraft and flight simulators. At the first stage, the company will get $813M to supply 351 Advanced Pilot Training aircraft and 46 simulators. The overall deadline is 2034.

This is just to name a few, and still one could clearly understand Boeing has orders for at least the next 10 years.

Boeing is also a significant player in the international military business; with the emerging countries increasing their budgets in the light of global geopolitical uncertainty, the company is sure to get more orders.

Apart from military aircraft, Boeing is planning to launch an air taxi prototype next year, which would carry passengers for short distances, while the company is also determined to create an air transport management system within 5 years.

All this makes the outlook perfect, with both dividends and share prices growing steadily. Technically, however, there is some extreme volatility, which shows investors are uncertain; some are closing their positions to lock in over 100% profit, others are, conversely, buying. This led to the price forming a wide range between $315 and $370. At this rate, it may well reach $400 and then bounce back to $300.

Technical Analysis

In 2016, Boeing shares started rising from $100, with the volumes growing, and reached the high at $350, i.e. those who bought at $100, started selling at $350. This means one should better wait for higher volumes and lower prices, as well as some good news, before buying, rather than going long straight away.

Alphabet Inc (NASDAQ: GOOG) experienced a similar situation, when the price was between $1,000 and $1,200, and then, when good earning reports came out, it reached $1,270. Then, Google shares went down again, and are now trading at $1,150, while being fundamentally very strong. So, it may start rising again soon, but at lower levels.

You remember an old saying ‘Buy rumors, sell facts’, of course. This is true with Boeing as well. The news on the company plans must be already priced into the shares, so before adding Boeing to your portfolio, you’d better wait for some lower prices.

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboMarkets shall not be held liable for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
1 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 5 (1 votes, average: 5.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 15 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Analysis

Investors Getting High on Cannabis

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

A year ago, you would hardly find even the most financially illiterate person in the world that had not heard of Bitcoin or cryptocurrency. Regardless of whether they know what it was — at least they know you can earn money with it!

Opportunities to earn easy money sometimes do appear, but they do extremely rarely, and in this light the crypto boom is often compared to the tulipmania that happened in the 17th century. At that time, speculators with no experience joined the tulip futures trading, which eventually led to a sharp increase in flower bulb prices, while a year later the overheated market collapsed, bringing huge losses to all.

The chance to earn huge profits for people who do not have a close connection with the markets does not appear so often. But for those who work with stocks, such opportunities arise almost every quarter.

The price of bitcoin at the peak of its popularity, when almost everyone knew about it, went up by 2,000%. In the stock market, some companies can yield a return of 1,000% within a week or a month, and there is no need to wait a whole year around.

The last sharp increase in share prices after an IPO, which broke all records this year, was shown by Tilray. Since the IPO on July 19 this year, the stock yielded a return of 1,300% over 2 months, and for those who follow the IPO, there was plenty of time to buy this stock, as the price was at about $20 for about a month.

Tilray is a Canada-based company specializing in cultivation and sale of medical marijuana to consumers and pharmaceutical distributors.

When a stock experiences such a rise, however, it usually falls afterwards, and Tilray was no exception as it lost 50% of its maximum value, although it continues to trade at 600% higher against the initial IPO price.

2018 was a landmark for marijuana manufacturers, as in January California legalized the use of marijuana for recreational purposes. Currently, medical marijuana products can be consumed in 29 US states. It is expected that, by 2022, the marijuana market in the US and Canada will have grown by more than three times.

Tilray is a clear indicator of investors’ interest in such companies. However, it’s not just traders who are interested in marijuana producers. Constellation Brands, one of the largest beer producers in the US, announced its intention to invest $4B into Canopy Growth, another Canadian company. This will allow it to increase its share in Canopy Growth from 8.70% to 38.00%. In the next 3 years, the US company will get the right to buy another 139.7M shares for $3.5B, thereby increasing its stake to the controlling one.

Meanwhile, Microsoft has partnered with the Kind Financial, a US based startup company which develops software for government agencies that control the production and sale of marijuana.

On September 17, rumor had it that Coca-Cola was negotiating with Aurora Cannabis to create a beverage containing cannabis. Most likely, this drink will be used to reduce inflammation, seizures, and as an anesthetic.

All this confirms the interest of large companies and investors in marijuana manufacturers. At this rate, finding a marijuana company and investing your money in it could seem a good idea, but there is a risk of high volatility, just like in case of Tilray, which can put your deposit under serious threat. An easier way would be investing in an ETF with the same companies stocks.

The most interesting ETF in the marijuana industry is ETFMG Alternative Harvest (NYSE: MJ).

According to some sources, since August 22, this fund recorded a cash inflow of $112M, which is about 20% of the total value of its entire portfolio. With the money supply growing, the trading volumes increased up to 10M shares, which is 3 times higher than the volume in July.

The interest towards this ETF was especially frantic when California passed the law early this year: at that time, ETF MJ price rose from $29 to $39. Then, in March, the price tried to go up further, but the volumes stayed low, so the price had to get back and even sank a bit. It was only in August when $27 got broken out, and then the price went well up to reach $45, this time also with increased trading volumes. Currently, the support levels are at $34 and $39. Given the increased volatility, the price is quite likely to go down to $34.

ETF investment has always been considered less risky, and in case we are now on the brink of a marijuana boom, this ETF is certainly going to be the best investment vehicle.

 

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboMarkets shall not be held liable for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
3 votes, average: 4.00 out of 53 votes, average: 4.00 out of 53 votes, average: 4.00 out of 53 votes, average: 4.00 out of 53 votes, average: 4.00 out of 5 (3 votes, average: 4.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 15 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Marijuana

Cannabis Maker Tilray Soars 50% amid U.S. Regulatory Green Light

Published

on

Medical cannabis maker Tilray (TLRY), which trades on the Nasdaq, has seen its stock expand by more than 50% today as the market cap races past $20 billion. As CNBC noted, Tilray dwarfs more than 100 companies in the S&P 500. Today’s gains are impressive, even for a stock that has gained about 900% since going public in July. Something to keep in mind is that on the fundamental side, Tilray only boasts $28 million in sales, suggesting that the stock has likely gotten ahead of itself. There’s reportedly been speculation about potential M&A involving Tilray and some rock-solid developments as well.

Meanwhile, the major indices are posting lackluster performances, which places the spotlight all the more on TLRY. Tilray has been buoyed by a couple of catalysts, not the least of which involves the regulatory green light to import cannabis into the lower 48 states for research. Additionally, Tilray chief Brendan Kennedy was featured on CNBC with Jim Cramer, which gave the company good exposure.

 

Source: Yahoo Finance

Kennedy in the “Mad Money” interview with Cramer pointed to a global medical marijuana market with the potential to be worth $150 billion despite all of the regulatory hurdles, one of which the company just cleared. It’s a market in which pharmaceutical giants need to play to remain competitive. Kennedy told Cramer:

“Cannabis is a substitute for prescription painkillers, prescription opioids, and so if you’re an investor in a pharmaceutical company or you’re a pharmaceutical company, you have to hedge the offset from cannabis substitution.”

Similarly, alcohol companies and investors need to jump in because “it’s a great hedge for them.”

Regulatory Bump

In a paradigm shift, the U.S. Drug Enforcement Administration (DEA) has handed regulatory approval to Tilray to import medical cannabis to the United States for research purposes. Tilray has partnered with the UC San Diego to start. It’s a major boon for the Canadian marijuana play that already has a presence in the U.S., as now its North American positioning will only be strengthened.

Not to mention the fact that Coca-Cola announced it’s exploring an expansion into the cannabis industry, too. The beverage giant is in discussion with Aurora Cannabis for a possible marijuana drink. It’s created a frenzy in the cannabis market akin to the early excitement surrounding the blockchain.

Similar to crypto, there’s a great deal of speculation that’s driving Tilray shares right now, and as Cramer pointed out “a lot of retail money,” which may not end well for everyone. Until then, all eyes are on Oct. 17, which is when cannabis is legalized for recreational use in Canada.

Featured image courtesy of Shutterstock.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
1 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 5 (1 votes, average: 5.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.6 stars on average, based on 69 rated postsGerelyn has been covering ICOs and the cryptocurrency market since mid-2017. She's also reported on fintech more broadly in addition to asset management, having previously specialized in institutional investing. She owns some BTC and ETH.




Feedback or Requests?

Continue Reading

Recent Comments

Recent Posts

A part of CCN

Hacked.com is Neutral and Unbiased

Hacked.com and its team members have pledged to reject any form of advertisement or sponsorships from 3rd parties. We will always be neutral and we strive towards a fully unbiased view on all topics. Whenever an author has a conflicting interest, that should be clearly stated in the post itself with a disclaimer. If you suspect that one of our team members are biased, please notify me immediately at jonas.borchgrevink(at)hacked.com.

Trending